FMR1 and fragile X syndrome: We showed that histone deacetylase inhibitors (butyrate and phenylbutyrate) alone did not reactivate FMR1 in FXS lymphoblastoid cell lines, but were synergistic with 5-azadC in reactivating the silent gene [72].